Department of Medicine , Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.
Lupus. 2010 Apr;19(4):436-9. doi: 10.1177/0961203310361487.
Anticardiolipin antibodies (aCL), anti-beta(2)-glycoprotein I (beta(2)GPI) antibodies and lupus anticoagulant (LA) are the only laboratory tests considered within the revised criteria for the classification of the antiphospholipid syndrome (APS). Recently, the significance to assay the antibodies against phosphatidylserine-prothrombin complex (aPS/PT) has been discussed, and these antibodies, rather than antibodies against prothrombin alone, are closely associated with APS and LA. The sensitivity and specificity of aPS/PT for the diagnosis of APS were assessed in a population of patients with a variety of autoimmune disorders. The aCL and aPS/PT have similar diagnostic value for APS, and most of APS patients with aPS/PT had positive LA. Therefore, aPS/PT should be further explored, not only for research purposes, but also as a candidate for one of the enzyme-linked immunosorbent assay (ELISA)-based confirmatory test for APS associated LA.
抗心磷脂抗体(aCL)、抗β2-糖蛋白 I(β2GPI)抗体和狼疮抗凝物(LA)是修订后的抗磷脂综合征(APS)分类标准中唯一考虑的实验室检测。最近,检测磷脂酰丝氨酸-凝血酶原复合物抗体(aPS/PT)的意义受到了讨论,这些抗体与 APS 和 LA 密切相关,而不仅仅是单独针对凝血酶原的抗体。在患有各种自身免疫性疾病的患者人群中,评估了 aPS/PT 对 APS 的诊断的敏感性和特异性。aCL 和 aPS/PT 对 APS 的诊断价值相似,大多数 aPS/PT 阳性的 APS 患者存在 LA 阳性。因此,应进一步探索 aPS/PT,不仅用于研究目的,还可以作为基于酶联免疫吸附试验(ELISA)的 APS 相关 LA 确认试验的候选方法之一。